BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Acute myeloid leukemia clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for acute myeloid leukemia: 197 (136 sponsors; 27 newly posted in the last 180 days, 19 stopped in the last 180 days; 15 new-entrant sponsors). Momentum score 2.8, rank 91 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 3, Phase 1 83, Phase 2 64, Phase 3 25, Phase 4 4, N/A 18.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AbbVie ABBV10NA 2, P3 3, P4 2, P2 2, P1 101
Actinium Pharmaceuticals ATNM2P3 200
Kura Oncology, Inc. KURA5P1 3, P3 1, P2 111
Taiho Oncology, Inc.5P2 2, P3 1, P1 202
Janssen Research & Development, LLC4P1 3, P3 100
Orca Biosystems, Inc.4P3 1, P2 1, P1 200
Syndax Pharmaceuticals SNDX4P3 1, P1 2, P2 111
Ascentage Pharma Group Inc. AAPG3P1 1, P2 1, P3 100
Daiichi Sankyo3P2 2, P3 101
Sichuan Baili Pharmaceutical Co., Ltd.3P1 2, P3 101
Beijing InnoCare Pharma Tech Co., Ltd.2P3 1, P1 110
Sellas Life Sciences Group SLS2P3 1, P2 101
Shijiazhuang Yiling Pharmaceutical Co. Ltd2P3 1, P1 100
Sunshine Lake Pharma Co., Ltd. SBFM2P3 1, P2 100
Hutchmed HCM1P3 100
Ipsen new entrant1P3 110
Moleculin Biotech, Inc. MBRX1P3 100
Otsuka Australia Pharmaceutical Pty Ltd1P3 100
Priothera SAS1P3 101
Quetzal Therapeutics1P3 101
SDK Therapeutics, Inc.1P3 100
Servier Affaires Médicales1P3 100
Bristol-Myers Squibb BMY3P2 2, NA 100
Novartis Pharmaceuticals NVS3P2 1, P1 1, P4 100
OncoVerity, Inc.3P2 2, P1 102

New-entrant sponsors: Ipsen.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P2Institut de Recherches Internationales Servier (I.R.I.S.)NCT06052813 A Study of BN104 in the Treatment of Acute LeukemiaALL, Adult; AML, Adult; Acute Leukaemia; KMT2A Rearrangement; NPM1 Mutation; NUP98 Gene Rearrangemenactive not recruiting66
2026-12 est.P2Ryvu Therapeutics SANCT06987058 RVU120 Rollover StudyAdvanced Solid Tumors; Acute Myeloid Leukaemia (AML); High-risk Myelodysplastic Syndromeenrolling by invitation14
2027-02 est.P1/P2AbbVie ABBVNCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaAcute Myeloid Leukemiaactive not recruiting218

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P1/P2Aptose Biosciences Inc.NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory AcuteLeukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML; Myelodysplastic Syndrome With Excess Brecruiting240
2026-09-08P1/P2BlueSphere Bio, IncNCT06704152 BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDSAML, Adult Recurrent; ALL, Recurrent, Adult; MDSterminated2
2026-08 est.P1/P2AB ScienceNCT05211570 AB8939 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaAcute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse; Myelodysplastic Syndrome Acutrecruiting78
2026-07-14P1/P2Ossium Health, Inc.NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignAcute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; Aactive not recruiting12
2026-06-20 est.P1/P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05055791 A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic MalignanciesAcute Myeloid Leukemia; Lymphoma; Multiple Myelomaunknown312
2026-06 est.P1/P2Advanced BioDesignNCT05601726 First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AMAcute Myeloid Leukemia, Adult; Myelodysplastic Syndromesrecruiting36

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "acute myeloid leukemia"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.